A phase III study to evaluate the safety and efficacy of house dust mite sublingual immunotherapy (Actair) in children with allergic rhinitis
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2017
At a glance
- Drugs S 524101 (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- 28 Mar 2017 According to a Stallergenes Greer plc media release, a New Drug Application (NDA) for ACTAIR, an investigational allergy immunotherapy sublingual tablet, for the treatment of house dust mite (HDM) induced allergic rhinitis in children 5 to 11 years old has been submitted in Japan. The submission is based on data from this trial.
- 27 Jan 2017 Based on the result of this study Shionogi is working towards getting the indication for five-to-eleven-year-old patients with allergic rhinitis caused by house dust mite, according to a company media release.
- 27 Jan 2017 Primary endpoint has been met. (Average adjusted symptoms score), as reported in a Shionogi Media Release.